News for Praxis Precision Medicines, Inc. (PRAX)

Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medici...

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.

**media[553406]**

On February 28, 2025, Praxis Precision Medicines Inc (PRAX), a clinical-stage biopharmaceutical company, announced an update on the interim analysis for Study 1

Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fou

On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a significant transaction involving Praxis Precision Medicines Inc (PRAX). The firm a

On December 31, 2024, Steven Cohen (Trades, Portfolio), a renowned figure in the investment world, executed a significant transaction involving Praxis Precision

On December 31, 2024, Cormorant Asset Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 823,219 shares of Praxis Precision M

Investors with a lot of money to spend have taken a bullish stance on Praxis Precision Medicine PRAX. And retail traders should know. We noticed this today wh...

**media[532262]**

**media[531201]**

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines Inc (PRAX), a clinical-stage biopharmaceutical company, has announced substantial advancements in its portfolio, focusing on therapie

Praxis Precision Medicines Inc (PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, an

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. ( PRAX), a clinical-stage biopharmaceutical company translating genetic insights in

Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Read more here.

**media[495555]**